MedPath

Dopamine modulation of oxytocin prosocial effects

Conditions
HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA
Therapeutic area: Psychiatry and Psychology [F] - Behaviours [F01]
Registration Number
EUCTR2011-006302-28-IT
Lead Sponsor
IVERSITA' DEGLI STUDI DI PARMA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Male
Target Recruitment
50
Inclusion Criteria

Male Caucasian, healthy subjects (age: 18-44 years) with negative history of neurological, medical and psychiatric diseases.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-negative history of neurological, medical and psychiatric diseases
-< 18 years
-> 55 years
- women

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: Characterize dopaminergic D2 system modulation on prosocial responses to oxytocin;Secondary Objective: Multimodal identification of cerebral responses associated with oxytocin;Primary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system;Timepoint(s) of evaluation of this end point: 3 years
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system;Timepoint(s) of evaluation of this end point: 3 years
© Copyright 2025. All Rights Reserved by MedPath